Rothschild & CO Asset Management Us Inc. Phathom Pharmaceuticals, Inc. Transaction History
Rothschild & CO Asset Management Us Inc.
- $6.56 Billion
- Q4 2022
A detailed history of Rothschild & CO Asset Management Us Inc. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Rothschild & CO Asset Management Us Inc. holds 245,658 shares of PHAT stock, worth $2.16 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
245,658
Previous 207,428
18.43%
Holding current value
$2.16 Million
Previous $2.3 Million
19.93%
% of portfolio
0.04%
Previous 0.04%
Shares
7 transactions
Others Institutions Holding PHAT
# of Institutions
144Shares Held
73.6MCall Options Held
42.3KPut Options Held
45.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$88.8 Million9.84% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$65.5 Million28.04% of portfolio
-
Jennison Associates LLC5.87MShares$51.5 Million0.07% of portfolio
-
Invesco Ltd. Atlanta, GA4.1MShares$36 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$30.7 Million9.52% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $344M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...